Drug of Abuse-Amphetamines By RAPID

Blood

Report in 4Hrs

At Home

No Fasting Required

Details

Rapid urine/blood screening panels.

₹222₹317

30% OFF

Drug of Abuse-Amphetamines By RAPID

Why is it done?
- Detects the presence of amphetamines and related compounds (including methamphetamine) in urine samples using rapid immunoassay technology
- Screens for substance abuse in workplace drug testing programs and employment-related evaluations
- Used in clinical settings to monitor patients with known or suspected amphetamine or methamphetamine use
- Ordered during medical evaluation for behavioral changes, psychiatric symptoms, or acute intoxication
- Required for legal or court-ordered drug testing, probation monitoring, or criminal justice evaluations
- Part of comprehensive substance abuse screening in addiction treatment or rehabilitation programs
- Performed as part of pre-employment or pre-operative medical clearance procedures
Normal Range
- Negative Result: No amphetamines or methamphetamine detected in the urine sample; typically reported as "Negative" or "Not Detected"
- Cutoff Threshold: Typically 500 ng/mL (nanograms per milliliter) for screening purposes, following SAMHSA (Substance Abuse and Mental Health Services Administration) guidelines
- Positive Result: Amphetamines or methamphetamine detected at or above the cutoff level; reported as "Positive"
- Borderline/Presumptive Positive: Results near the cutoff threshold that may require confirmatory testing via GC-MS (gas chromatography-mass spectrometry)
- Units of Measurement: ng/mL (nanograms per milliliter) of urine
- Interpretation: Negative = No recent amphetamine use detected; Positive = Possible recent use requiring confirmation
Interpretation
- Negative Result: No amphetamines detected above the screening threshold, suggesting no recent use of amphetamine or methamphetamine (within approximately 48 hours)
- Positive Result: Indicates presumptive use of amphetamines or methamphetamine; this is a screening test and requires confirmatory testing by GC-MS for definitive results
- Clinical Significance of Amphetamine Detection: May indicate recent illicit amphetamine or methamphetamine use; however, prescription amphetamines (Adderall, dextroamphetamine) used therapeutically for ADHD, narcolepsy, or obesity may also produce positive results
- Factors Affecting Results: Timing of sample collection (amphetamines are detectable for 24-72 hours post-use); urine concentration (dilute vs. concentrated samples); individual metabolism rates; concurrent use of other substances; certain medications containing amphetamine compounds; potential cross-reactivity with ephedrine, phenylephrine, or pseudoephedrine
- False Positive Considerations: Rapid screening tests can produce false positives; over-the-counter cold medications, decongestants, diet pills, and some herbal supplements may cause positive results; confirmatory testing distinguishes true positives from false positives
- RAPID Test Advantages: Provides quick results (often within minutes), making it suitable for point-of-care testing in emergency departments, clinics, and workplace settings
- Prescription Medication Disclosure: Patient should disclose use of prescription amphetamines or related medications to ensure proper interpretation of results
Associated Organs
- Primary System Affected: Central nervous system (CNS) and kidneys; urine is examined as a non-invasive marker of systemic amphetamine exposure
- Neurological Effects of Amphetamines: Stimulate dopamine and norepinephrine release; can cause agitation, anxiety, paranoia, insomnia, seizures, and psychosis
- Cardiovascular Effects: Increased heart rate, elevated blood pressure, arrhythmias, myocardial infarction, and stroke associated with amphetamine use
- Respiratory System: Increased respiratory rate; potential for pulmonary edema in cases of overdose
- Hepatic Metabolism: Amphetamines are metabolized in the liver; chronic use may be associated with liver dysfunction
- Associated Medical Conditions: Substance use disorder, amphetamine intoxication, acute psychiatric symptoms, behavioral disturbances, withdrawal syndromes, cardiovascular disease, hypertensive crisis, stroke, myocardial infarction
- Potential Complications: Overdose with potential for fatal outcomes; acute kidney injury; hyperthermia; rhabdomyolysis; disseminated intravascular coagulation (DIC); secondary psychiatric disorders; chronic neurotoxicity affecting cognitive function
Follow-up Tests
- Confirmatory Testing - Gas Chromatography-Mass Spectrometry (GC-MS): Gold standard for confirming presumptive positive results; differentiates amphetamine from methamphetamine and identifies specific metabolites
- Comprehensive Urine Drug Screen: Testing for multiple substances including opioids, cocaine, cannabinoids, benzodiazepines, and barbiturates to assess for polydrug use
- Basic Metabolic Panel (BMP): Assess kidney function, electrolytes, and glucose levels if amphetamine toxicity or acute intoxication is suspected
- Cardiac Evaluation: Electrocardiogram (ECG) and troponin levels if acute coronary syndrome or arrhythmias are suspected secondary to amphetamine use
- Creatinine Kinase (CK): To detect rhabdomyolysis or myositis associated with severe amphetamine intoxication
- Psychiatric and Behavioral Assessment: Evaluation by mental health professionals for acute psychiatric symptoms, substance use disorder assessment, and addiction treatment planning
- Repeat Testing for Monitoring: Periodic drug screening during addiction treatment; frequency typically ranges from weekly to monthly based on treatment protocol and compliance needs
- Urinalysis with Microscopy: To assess sample validity and quality; checks for dilution, contamination, or specimen tampering
- Neuroimaging Studies: MRI or CT of brain if stroke, intracranial hemorrhage, or other acute neurological complications are suspected
Fasting Required?
- Fasting Required: No
- Special Preparation: Patient may eat and drink normally; fasting is not necessary for drug screening tests
- Specimen Collection: Random urine sample collected in a provided sterile container; morning first-void specimen is often preferred for higher concentration of analytes
- Chain of Custody: Strict adherence to chain of custody procedures required for medico-legal cases; specimen must be sealed, labeled with patient identification, date, and time
- Medications to Disclose: Inform healthcare provider of prescription medications including amphetamine-based drugs (Adderall, dextroamphetamine), decongestants, diet pills, and herbal supplements that may interfere with results
- Medications to Avoid: No specific medications need to be avoided; however, over-the-counter cold remedies containing pseudoephedrine, phenylephrine, or ephedrine may cause false positive results and should be disclosed
- Additional Instructions: Specimen must be collected in a secure, observed setting for workplace or legal testing; patient should not touch the sample; adequate volume (typically 30-60 mL) required for testing
- Timing of Sample Collection: Best obtained 2-48 hours after suspected amphetamine use for maximum detection sensitivity

How our test process works!